[lu-177]-pnt2002,abiraterone,enzalutamide
pfizer,astellas,point biopharma,janssen
['splash', 'crpc']
"#pressrelease: point biopharma provides updated efficacy and safety data from the lead-in cohort of the phase 3 splash trial in mcrpc at esmo congress 2022 #news": 
Flying the web for trusted world news reports and shopping discounts 24/7. Retweeting for opinions, useful information, and the many voices of Twitter.